Results 231 to 240 of about 125,713 (396)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia. [PDF]

Ann Hematol
Turkina A, Vinogradova O, Lomaia E, Shatokhina E, Shukhov O, Chelysheva E, Shikhbabaeva D, Nemchenko I, Petrova A, Bykova A, Siordiya N, Shuvaev V, Mikhailov I, Novikov F, Shulgina V, Hochhaus A, Ottmann O, Cortes J, Gale RP, Chilov G.   +19 more
europepmc   +2 more sources

Chronic myeloid leukaemia presenting as venous stasis retinopathy [PDF]

, 2004
S. Salvi
openalex   +1 more source

Is there really an accelerated phase of chronic myeloid leukaemia? [PDF]

Leukemia
Gale RP, Jiang Q, Apperley JF, Hochhaus A.   +3 more
europepmc   +1 more source

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions. [PDF]

BMC Med Genomics, 2023
May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S, Genomics England Research Consortium, Willis F, Apperley JF, Innes AJ.   +9 more
europepmc   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, EarlyView.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants [PDF]

, 2004
Jakob Passweg, Irwin Walker, Kathleen A. Sobocinski, John P. Klein, Mary M. Horowitz, Sergio Giralt   +5 more
openalex   +1 more source

Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids

International Journal of Cancer, EarlyView.
What's New? Poor prognosis in cholangiocarcinoma (CCA) is attributed to late diagnosis and intrinsic chemoresistance. In particular, resistance mechanisms that suppress apoptosis limit the effectiveness of gemcitabine‐based regimens, which remain the standard treatment.
Wunan Mi, Gilles S. van Tienderen, Shaojun Shi, Amy Broeders, Kathryn Monfils, Henk P. Roest, Luc J. W. van der Laan, Monique M. A. Verstegen   +7 more
wiley   +1 more source

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

British Journal of Haematology, 2018
D. Réa, F. Mahon
semanticscholar   +1 more source

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting. [PDF]

Br J Haematol
Suttorp M, Sembill S, Lensker P, Hildebrand V, Schirmer E, Karow A, Krumbholz M, Rauh M, Metzler M.   +8 more
europepmc   +1 more source